Background International time trends in asthma mortality have been strongly affected by
changes in management and in particular drug treatments. However, little is known about …

Concerns about the safety of long-acting β2-agonist (LABA) therapy, has led to the
appearance of multiple publications and recommendations. This review critically examines …

Background: There is concern that long-acting β agonist (LABA) drugs may increase the risk
of asthma mortality. Methods: A meta-analysis was conducted of asthma deaths in …

Methods Death records and mid-year population data were collected from the National
Statistics Institute. Using the direct method, agestandardized mortality rates were calculated …

The introduction of long-acting b-agonist (LABA) drugs in the 1990s was considered a major
advance in bronchodilator therapy with evidence that their use led to improved lung function …

Despite major advances in the understanding of the pathogenesis of asthma and
improvements in management, the accompanying benefits from public health initiatives and …

Possible adverse effects of adrenergic bronchodilators in asthma have been the subject of
discussion for more than half a century, with recent intense debate about the safety of …

''When EF Hutton speaks, people listen''was the catchy and memorable slogan of this
brokerage house decades ago and was based on the premise that EF Hutton knew what he …

Importance of the field: Pooled trial data have shown that long-acting β-agonists increase
the risk for asthma hospitalizations and deaths by two to fourfold compared with placebo …

A number of concerns were voiced in 2006 regarding the safety of the use of long-acting β-
agonists (LABAs) for treatment of asthma. These concerns included whether use of this class …